On September 12, NMPA held 2023 ICH in China: Progress and Outlook Symposium in Beijing, to make dialogue on development and cooperation with representatives from domestic and foreign industry associations. Huang Guo, Deputy Commissioner of China NMPA attended and addressed at the meeting.

　　Huang Guo stated that China is deeply involved in global drug safety governance and continuously deepening international cooperation. Through joining International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and becoming an ICH management committee member, NMPA has been actively learning from and sharing with international peers, accelerating the coordination and harmonization of regulatory rules, promoting mutual recognition of international regulation, and jointly enhancing the development of the global pharmaceutical industry.

　　He emphasized that the NMPA is willing to work together with all parties, adhere to the patient-focused concept, stick to the scientific, governance-by-law, international, and modernized path of development, continue to deepen drug regulatory reform and innovation, and accelerate the approval of drugs that are urgently needed on clinical side, so as to further expand external opening up and high-quality international cooperation, jointly foster a good ecosystem for high-quality development of the pharmaceutical industry, and protect and promote public health.